⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4427633 | 0.70 | CHEK1 (0.44) | — | |
| SCHEMBL35083 | 0.68 | — | — | |
| SCHEMBL291015 | 0.65 | — | — | |
| SCHEMBL1652354 | 0.64 | PDE3B (0.39) | — | |
| SCHEMBL241978 | 0.64 | — | — | |
| SCHEMBL901559 | 0.64 | — | — | |
| SCHEMBL7403740 | 0.62 | XDH (0.35) | — | |
| SCHEMBL128415 | 0.60 | — | — | |
| SCHEMBL768801 | 0.60 | — | — | |
| SCHEMBL15062476 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3568 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370110-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2024-05-22 | — | — | EP | claimed |
| CN-117940120-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-04-26 | — | — | CN | claimed |
| EP-3901147-B1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | claimed |
| WO-2023208130-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2023-11-02 | — | — | WO | claimed |
| WO-2023138675-A1 | QUINOLINE COMPOUND AND USE THEREOF | 默达药物（香港）有限公司 | 2023-07-27 | — | — | WO | claimed |
| WO-2023138674-A1 | N-HYDROXYQUINOLINE CARBOXAMIDE COMPOUND AND USE THEREOF | 默达药物（香港）有限公司 | 2023-07-27 | — | — | WO | claimed |
| WO-2023118507-A2 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2023-06-29 | — | — | WO | claimed |
| US-11649324-B2 | Highly pure thionated polymers | BRIMSTONE HOLDING LLC (US) | 2023-05-16 | — | — | US | claimed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | claimed |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | claimed |
| EP-1140873-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | Janssen Pharmaceutica N.V. (BE) | 2001-10-10 | — | — | EP | claimed |
| EP-1133482-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-19 | — | — | EP | claimed |
| EP-1133483-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-19 | — | — | EP | claimed |
| EP-1114046-A1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | Janssen Pharmaceutica N.V. (BE) | 2001-07-11 | — | — | EP | claimed |
| WO-2000037451-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-29 | — | — | WO | claimed |
| WO-2000031054-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-02 | — | — | WO | claimed |
| WO-2000031053-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-02 | — | — | WO | claimed |
| WO-2000017195-A1 | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-03-30 | — | — | WO | claimed |
| EP-0987265-A1 | Interleukin-5 inhibiting 6-azauracil derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-03-22 | — | — | EP | claimed |
| US-4113867-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1978-09-12 | — | — | US | claimed |